Trial · NCT04892446
Results by group49
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 49
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Magrolimab+Daratumumab | 16.7 | percentage of participants | ||
| Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Magrolimab+Pomalidomide+Dexamethasone | 16.7 | percentage of participants | ||
| Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Magrolimab+Carfilzomib+Dexamethasone | 0 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE's) According to the NCI CTCAE Version 5.0 | Magrolimab+Daratumumab | 100 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE's) According to the NCI CTCAE Version 5.0 | Magrolimab+Pomalidomide+Dexamethasone | 100 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE's) According to the NCI CTCAE Version 5.0 | Magrolimab+Carfilzomib+Dexamethasone | 100 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 | Magrolimab+Daratumumab | Hematology: Any Grade 1 or Higher | 92.9 | percentage of participants | |
| Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 | Magrolimab+Pomalidomide+Dexamethasone | Hematology: Any Grade 1 or Higher | 100 | percentage of participants | |
| Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 | Magrolimab+Carfilzomib+Dexamethasone | Hematology: Any Grade 1 or Higher | 100 | percentage of participants | |
| Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 | Magrolimab+Daratumumab | Chemistry: Any Grade 1 or Higher | 92.9 | percentage of participants | |
| Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 | Magrolimab+Pomalidomide+Dexamethasone | Chemistry: Any Grade 1 or Higher | 100 | percentage of participants | |
| Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 | Magrolimab+Carfilzomib+Dexamethasone | Chemistry: Any Grade 1 or Higher | 100 | percentage of participants | |
| Objective Response Rate (ORR) | Magrolimab+Daratumumab | 14.3 | 95% Confidence Interval 1.8 to 42.8 | percentage of participants | |
| Objective Response Rate (ORR) | Magrolimab+Pomalidomide+Dexamethasone | 20.0 | 95% Confidence Interval 2.5 to 55.6 | percentage of participants | |
| Objective Response Rate (ORR) | Magrolimab+Carfilzomib+Dexamethasone | 36.4 | 95% Confidence Interval 10.9 to 69.2 | percentage of participants | |
| Duration of Response (DoR) | Magrolimab+Daratumumab | NA | 95% Confidence Interval NA to NA | months | |
| Duration of Response (DoR) | Magrolimab+Pomalidomide+Dexamethasone | NA | 95% Confidence Interval 3.9 to NA | months | |
| Duration of Response (DoR) | Magrolimab+Carfilzomib+Dexamethasone | NA | 95% Confidence Interval NA to NA | months | |
| Serum Concentration of Magrolimab | Magrolimab+Daratumumab | Predose: Cycle 1 Day 1 | NA | Standard Deviation NA | ng/mL |
| Serum Concentration of Magrolimab | Magrolimab+Pomalidomide+Dexamethasone | Predose: Cycle 1 Day 1 | NA | Standard Deviation NA | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04892446/results